- Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY) inks an agreement to acquire Gosselies, Belgium-based clinical-stage drug discovery outfit Ogeda for up to €800M. Under the terms of the deal, Astellas will make an upfront payment of €500M for 100% of Ogeda's equity and up to €300M in milestones. The transaction should close in Q2.
- Ogeda discovers and develops small molecule drugs targeting G-protein-coupled receptors. Its lead product candidate is Phase 2-stage fezolinetant, a selective NK3 receptor antagonist for the non-hormonal treatment of menopause-related vasomotor symptoms.
Astellas to acquire Belgian drug discovery firm Ogeda for up to €800M
This was corrected on 06/10/2022 at 11:06 AM. Ogeda is based in Belgium.
Recommended For You
About ALPMF Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALPMF | - | - |
Astellas Pharma Inc. |